Opinion: Biotech stocks have been hit by ‘DOGE’ and other fears. Why they’re a great value now. - MarketWatch

1. Biotech stocks are nearing extreme low sentiment, indicating a potential buying opportunity. 2. Pfizer earmarked $10 billion for acquisitions, showcasing investor interest in biotech. 3. Recent insider buying highlights confidence in Pfizer's prospects and strong balance sheet. 4. Inventories in the biotech sector signal a potential resurgence in drug approvals. 5. Expected Senate report may recognize biopharma as vital for national security.